Less than a two weeks ago we expressed a bullish view for healthcare stocks to play a bit of catch up with the S&P 500 (SPX) as it approached its prior all time highs, choosing …
Continue readingCELG
For week’s now my co-panelist on CNBC’s Options Action, Carter Worth of Cornerstone Macro Research has been making the bullish case for the Biotech stocks, specifically looking at the IBB, the iShares Nasdaq Biotech etf. …
Continue readingWhen market participants lack confidence in the underpinnings of the investment environment they quickly turn to technical analysis as their main trading input (there are some traditionalists with a long timer horizon that still view …
Continue readingI n 2015, the Nasdaq Composite is the runaway U.S. equity winner. You know the score there, some of the largest mega cap biotech & tech stocks in the market weighted average index are up …
Continue readingThis is the investment environment we live in. Celgene (CELG), a $98 billion market cap company that had $7.7 billion in sales in 2014, agrees to pay $7.3 billion for Receptos (RCPT), a biotech company …
Continue readingHere is some generally directional, untied options activity that caught my eye during Tuesday’s trading: 1. FXE – minutes before the close the etf that tracks the Euro saw a massive put spread purchase. When the etf was …
Continue readingFor the second year in a row, Healthcare is leading the pack by way of sector leadership: The chart of the XLV over the last three years is a work of art, up about 110% …
Continue readingBack in March the biotechnology sector was hard hit hard alongside social media, solar and 3d printing. Since then, most of these sectors have recovered most of their losses from that sell-off. Which brings us …
Continue readingOn Monday (below) I made the case why UA was likely oversold on a near term basis in front of the company’s addition to the S&P500 on last night’s close. As the stock approached technical …
Continue readingThe biotech sector was the talk of the town on Friday. The biotech ETF, IBB, was down almost 5%, and biotech shares led the Nasdaq and the healthcare sector lower. The Big Four, AMGN, GILD, …
Continue reading